What is Solid Biosciences Inc.'s D&A?

Solid Biosciences Inc. (SLDB) reported D&A of $395K in Q1 2026.

How has Solid Biosciences Inc.'s D&A changed year-over-year?

Solid Biosciences Inc.'s D&A decreased by 2.9% year-over-year, from $407K to $395K.

What is the long-term trend for Solid Biosciences Inc.'s D&A?

Over 4 years (2021 to 2025), Solid Biosciences Inc.'s D&A has grown at a -13.8% compound annual growth rate (CAGR), from $2.96M to $1.64M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Solid Biosciences Inc. SLDB D&A

D&A at other companies

Sarepta Therapeutics, Inc.SRPT

$10.59M+6.2%

BiogenBIIB

$204.4M+11.6%

Neurocrine BiosciencesNBIX

$7.2M+9.1%

InsmedINSM

$2.93M+55.8%

Dyne Therapeutics, Inc.DYN

$550K+9.6%

Taysha Gene Therapies, Inc.TSHA

$295K+4.2%

Other financials

Income statement

See full

Revenue$2.0M-40.6%

Operating income-$57.3M-43.1%

Net income-$56.7M-44.4%

EPS (diluted)-$0.52+11.9%

Balance sheet

See full

Cash & equivalents$297.1M+41.1%

Total debt$20.7M-12.5%

Total equity$374.1M+27.1%

Total assets$422.9M+23.0%

Cash flow

See full

Operating cash flow-$47.2M-48.3%

CapEx$165.0K+31.0%

Free cash flow-$47.4M-48.2%

Valuation

See full

Market cap$910.66M+135%

Enterprise value$634.23M+223%

P/S112.5×-10.3×

Profitability

See full

Operating margin-1,315.2%-4,060pp

Net margin-1,062.3%-251,151pp

FCF margin-1,247.7%-9,569pp

Returns & leverage

See full

Return on equity-57.4%+2.2pp

Debt / equity0.1×0.0×

Current ratio13.1×+2.2×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Solid Biosciences Inc.'s D&A?: Solid Biosciences Inc. (SLDB) reported D&A of $395K in Q1 2026.
How has Solid Biosciences Inc.'s D&A changed year-over-year?: Solid Biosciences Inc.'s D&A decreased by 2.9% year-over-year, from $407K to $395K.
What is the long-term trend for Solid Biosciences Inc.'s D&A?: Over 4 years (2021 to 2025), Solid Biosciences Inc.'s D&A has grown at a -13.8% compound annual growth rate (CAGR), from $2.96M to $1.64M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.